spread
global
pandem
within
month
onset
motiv
develop
rapidli
scalabl
vaccin
present
selfamplifi
rna
encod
spike
protein
encapsul
within
lipid
nanoparticl
vaccin
demonstr
induct
robust
neutral
pseudoviru
proport
quantiti
specif
igg
higher
quantiti
recov
patient
data
provid
insight
vaccin
design
evalu
immunogen
enabl
rapid
translat
clinic
unpreced
rapid
spread
global
pandem
current
estim
number
confirm
case
million
peopl
motiv
need
rapidli
produc
scalabl
vaccin
coronavirus
positivesens
singl
strand
rna
virus
caus
diseas
patholog
rang
common
cold
pneumonia
despit
list
blueprint
prioriti
list
current
licens
vaccin
sar
mer
howev
previou
studi
elucid
need
stabil
coronaviru
spike
protein
prefus
conform
order
serv
vaccin
immunogen
selfamplifi
rna
sarna
encapsul
lipid
nanoparticl
lnp
highli
relev
platform
produc
vaccin
context
global
pandem
possibl
encod
antigen
interest
requir
minim
dose
compar
messeng
rna
mrna
first
rna
therapeut
formul
lnp
approv
set
preced
clinic
safeti
lnpformul
rna
compar
immunogen
sarna
encod
prefus
stabil
spike
protein
encapsul
lnp
preclin
murin
model
immun
respons
gener
natur
infect
recov
patient
character
humor
cellular
respons
well
neutral
capac
pseudotyp
viru
confirm
express
prefus
stabil
spike
protein
vitro
supplementari
figur
mice
immun
sarna
encod
spike
protein
encapsul
lnp
dose
rang
g
figur
mice
receiv
two
inject
one
month
apart
electropor
plasmid
dna
pdna
use
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
posit
control
sarna
encod
rabi
glycoprotein
rabv
pabol
use
neg
control
week
observ
remark
high
quantiti
specif
igg
mous
sera
doserespons
manner
rang
ngml
figur
group
receiv
dose
g
sarna
lnp
significantli
higher
mice
receiv
g
electropor
pdna
respect
sarna
lnpvaccin
mice
even
g
group
higher
quantiti
specif
igg
compar
patient
recov
mean
titer
ngml
rang
ngml
importantli
pdna
sarna
lnp
immun
induc
respons
mice
supplementari
sought
character
antibodi
gener
immun
compar
gener
natur
infect
far
capac
neutral
pseudotyp
viru
figur
observ
highli
effici
viral
neutral
vari
linear
dosedepend
manner
mice
vaccin
sarna
lnp
ic
valu
rang
group
receiv
g
sarna
lnp
significantli
higher
electropor
pdna
posit
control
group
p
comparison
ic
valu
recov
patient
averag
ic
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
correl
igg
neutral
ic
vaccin
mice
recov
patient
electropor
pdna
dna
ep
use
posit
control
sarna
encod
rabi
glycoprotein
rabv
pabol
use
neg
control
rabv
control
indic
signific
p
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
also
character
cellular
respons
induct
system
cytokin
respons
vaccin
sarna
lnp
figur
observ
splenocyt
vaccin
mice
restimul
librari
peptid
yield
remark
high
secret
quantifi
elispot
figur
sarna
lnp
group
receiv
g
rang
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
figur
cellular
secret
cytokin
respons
sarna
lnp
vaccin
quantif
splenocyt
upon
restimul
peptid
express
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
spot
form
unit
sfu
per
cell
electropor
pdna
ep
pdna
use
posit
control
sarna
encod
rabi
glycoprotein
rabv
pabol
use
neg
control
rabv
control
bg
cytokin
profil
sera
mice
hour
vaccin
lnp
vaccin
remain
cytokin
found
supplementari
figur
character
immunogen
sarna
lnp
vaccin
compar
immun
respons
natur
infect
recov
patient
observ
two
sarna
lnp
immun
induc
remark
high
specif
igg
antibodi
mice
quantiti
superior
ep
pdna
natur
infect
human
abl
effici
neutral
pseudotyp
viru
also
observ
sarna
lnp
vaccin
induc
robust
cellular
respons
partial
enabl
potent
lnp
formul
observ
sarnaencod
prefus
stabil
spike
protein
use
studi
highli
immunogen
yield
antibodi
titer
ngml
figur
superior
other
report
subunit
vaccin
sar
mer
coronavirus
furthermor
observ
higher
antibodi
titer
viral
neutral
ic
cellular
respons
lnpformul
sarna
electropor
pdna
postul
due
potent
lnp
use
studi
previou
comparison
polyplexformul
sarna
ep
pdna
yield
similar
immunogen
highli
use
translat
mean
potent
lnpformul
sarna
vaccin
inject
wide
accept
syring
needl
requir
electropor
instrument
envis
enabl
widespread
vaccin
curb
spread
sarna
lnp
vaccin
present
studi
elicit
robust
antibodi
cellular
respons
bia
hypothes
enabl
immunogen
human
ongo
studi
carri
character
potenti
antibodi
depend
enhanc
ade
observ
sar
mer
role
phenomena
vaccineinduc
immun
yet
fulli
understood
overal
believ
data
inform
antigen
design
formul
preclin
evalu
immunogen
enabl
rapid
translat
vaccin
clinic
trial
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
use
plasmid
vector
synthes
selfamplifi
rna
sarna
replicon
base
trinidad
donkey
venezuelan
equin
enceph
viru
strain
veev
alphaviru
genom
viral
structur
protein
driven
subgenom
promot
replac
surfac
spike
glycoprotein
novel
sever
acut
respiratori
syndrom
coronaviru
genbank
access
number
modif
prefus
state
spike
glycoprotein
stabil
prolin
substitut
synthes
oligonucleotid
fragment
encod
gene
use
geneart
string
thermo
fisher
scientif
assembl
plasmid
vector
neb
hifi
assembl
new
england
biolab
express
plasmid
express
prefus
stabil
full
length
transmembran
protein
use
backbon
directli
synthes
clone
vector
geneart
thermo
fisher
scientif
plasmid
express
solubl
prewa
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
plasmid
express
solubl
prefus
version
use
produc
recombin
protein
use
express
system
thermo
fisher
scientif
accord
manufactur
instruct
condit
medium
clarifi
centrifug
protein
sequenti
purifi
histrap
hp
column
hiprep
sephacryl
hr
size
exclus
chromatographi
sec
column
ge
healthcar
purifi
protein
first
analyz
nativepag
western
blot
filter
membran
aliquot
store
selfamplifi
rna
encod
prefus
stabil
produc
use
vitro
transcript
pdna
transform
e
coli
new
england
biolab
uk
cultur
ml
luria
broth
lb
gml
carbenicillin
sigma
aldrich
uk
plasmid
purifi
use
plasmid
plu
maxiprep
kit
qiagen
uk
concentr
puriti
measur
nanodrop
one
thermofish
uk
pdna
linear
use
mlui
uncap
vitro
rna
transcript
produc
use
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
sampl
analyz
lsrforterssa
bd
bioscienc
facsdiva
softwar
bd
bioscienc
data
analyz
use
flowjo
version
flowjo
llc
sarna
encapsul
lnp
use
selfassembl
process
aqueou
solut
sarna
rapidli
mix
ethanol
lipid
mixtur
lnp
use
studi
similar
composit
describ
previous
contain
ioniz
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
rabv
control
group
formul
kda
pabol
ratio
polym
rna
ww
use
titrat
method
previous
describ
assess
cell
respons
perform
use
mous
elispot
plu
kit
mabtech
follow
manufactur
instruct
briefli
precoat
plate
block
dmem
fb
least
cell
ad
overnight
incub
develop
per
manufactur
protocol
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
dri
plate
read
use
aid
elispot
reader
aid
elispot
reader
softwar
autoimmun
diagnostika
gmbh
antigenspecif
igg
titr
mous
sera
assess
semiqu
elisa
previous
describ
brief
maxisorp
high
bind
elisa
plate
hivpseudotyp
luciferasereport
base
system
use
assess
neutral
abil
sera
vaccin
anim
recov
patient
sarscov
merscov
previous
describ
modif
brief
cov
subsequ
aliquot
store
neutral
assay
heatinactiv
sera
first
serial
dilut
incub
viru
h
serumviru
mixtur
transfer
well
preseed
cell
cell
lyse
luciferas
activ
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
